Critical roles of chemoresistant effector and regulatory T cells in antitumor immunity after lymphodepleting chemotherapy

Journal of Immunology

Volumn 195, Issue 2, 2015, Pages 726-735

  Saida, Yu ^a   Watanabe, Satoshi ^a   Tanaka, Tomohiro ^a   Baba, Junko ^a   Sato, Ko ^a   Shoji, Satoshi ^a   Igarashi, Natsue ^a   Kondo, Rie ^a   Okajima, Masaaki ^a   Koshio, Jun ^a   Ichikawa, Kosuke ^a   Nozaki, Koichiro ^a   Ishikawa, Daisuke ^a   Koya, Toshiyuki ^a   Miura, Satoru ^a   Tanaka, Junta ^a   Kagamu, Hiroshi ^a   Yoshizawa, Hirohisa ^a   Nakata, Koh ^a   Narita, Ichiei ^a  

^a NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; GEMCITABINE; PACLITAXEL; 3 METHYLCHOLANTHRENE; CYTOTOXIN; DEOXYCYTIDINE; VIDARABINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CD4+ CD25+ FOXP3 REGULATORY T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DOSE ESCALATION; FEMALE; FIBROSARCOMA; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; LYMPH NODE CELL; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPH NODE; LYMPHOPENIA; PATHOLOGY; TUMOR CELL CULTURE; WHOLE BODY RADIATION;

ADOPTIVE TRANSFER; ANIMALS; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXINS; DEOXYCYTIDINE; DRUG RESISTANCE; ETOPOSIDE; FEMALE; FIBROSARCOMA; LYMPH NODES; LYMPHOCYTE DEPLETION; LYMPHOPENIA; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PACLITAXEL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 84936796881     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401468     Document Type: Article

References (57)

1. North, R. J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155: 1063-1074.
2. North, R. J. 1984. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol. Immunother. 16: 175-181.
3. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
4. Rosenberg, S. A. 2011. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat. Rev. Clin. Oncol. 8: 577-585.
5. Dummer, W., A. G. Niethammer, R. Baccala, B. R. Lawson, N. Wagner, R. A. Reisfeld, and A. N. Theofilopoulos. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110: 185-192.
6. Goldrath, A. W., L. Y. Bogatzki, and M. J. Bevan. 2000. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 192: 557-564.
7. King, C., A. Ilic, K. Koelsch, and N. Sarvetnick. 2004. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117: 265-277.
8. Ma, J., W. J. Urba, L. Si, Y. Wang, B. A. Fox, and H. M. Hu. 2003. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur. J. Immunol. 33: 2123-2132.
9. Yoshizawa, H., A. E. Chang, and S. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147: 729-737.
10. Wang, L. X., S. Shu, M. L. Disis, and G. E. Plautz. 2007. Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 109: 4865-4876.
11. Baba, J., S. Watanabe, Y. Saida, T. Tanaka, T. Miyabayashi, J. Koshio, K. Ichikawa, K. Nozaki, T. Koya, K. Deguchi, et al. 2012. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 120: 2417-2427.
12. Shu, S. Y., and S. A. Rosenberg. 1985. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 45: 1657-1662.
13. Hiura, T., H. Kagamu, S. Miura, A. Ishida, H. Tanaka, J. Tanaka, F. Gejyo, and H. Yoshizawa. 2005. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J. Immunol. 175: 5058-5066.
14. Yoshizawa, H., K. Sakai, A. E. Chang, and S. Y. Shu. 1991. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 134: 473-479.
15. Watanabe, S., K. Deguchi, R. Zheng, H. Tamai, L. X. Wang, P. A. Cohen, and S. Shu. 2008. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J. Immunol. 181: 3291-3300.
16. Wrzesinski, C., C. M. Paulos, L. Gattinoni, D. C. Palmer, A. Kaiser, Z. Yu, S. A. Rosenberg, and N. P. Restifo. 2007. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117: 492-501.
17. Dudley, M. E., J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive mye-loablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
18. Wrzesinski, C., C. M. Paulos, A. Kaiser, P. Muranski, D. C. Palmer, L. Gattinoni, Z. Yu, S. A. Rosenberg, and N. P. Restifo. 2010. Increased intensity lympho-depletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33: 1-7.
19. Zheng, R., J. Kjaergaard, W. T. Lee, P. A. Cohen, and S. Shu. 2007. Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. Cancer Treat. Res. 135: 223-237.
20. Kagamu, H., and S. Shu. 1998. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160: 3444-3452.
21. Yoshizawa, H., A. E. Chang, and S. Y. Shu. 1992. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res. 52: 1129-1136.
22. Kim, R., M. Emi, K. Tanabe, and K. Arihiro. 2006. Tumor-driven evolution of im-munosuppressive networks during malignant progression. Cancer Res. 66: 5527-5536.
23. Rabinovich, G. A., D. Gabrilovich, and E. M. Sotomayor. 2007. Immunosup-pressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25: 267-296.
24. Baniyash, M. 2004. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 4: 675-687.
25. Williams, K. M., F. T. Hakim, and R. E. Gress. 2007. T cell immune reconsti-tution following lymphodepletion. Semin. Immunol. 19: 318-330.
26. Galluzzi, L., L. Senovilla, L. Zitvogel, and G. Kroemer. 2012. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 11: 215-233.
27. Chen, G., and L. A. Emens. 2013. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol. Immunother. 62: 203-216.
28. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912.
29. Klebanoff, C. A., H. T. Khong, P. A. Antony, D. C. Palmer, and N. P. Restifo. 2005. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26: 111-117.
30. Muranski, P., and N. P. Restifo. 2009. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr. Opin. Immunol. 21: 200-208.
31. Haabeth, O. A. W., A. A. Tveita, M. Fauskanger, F. Schjesvold, K. B. Lorvik, P. O. Hofgaard, H. Omholt, L. A. Munthe, Z. Dembic, A. Corthay, and B. Bogen. 2014. How do CD4(+) T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front. Immunol. 5: 174.
32. Quezada, S. A., and K. S. Peggs. 2011. Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities. Immunotherapy 3: 915-917.
33. Xie, Y., A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane, E. K. M. Kwon, P. Muranski, N. P. Restifo, and P. A. Antony. 2010. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207: 651-667.
34. Pardoll, D. M., and S. L. Topalian. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10: 588-594.
35. Antony, P. A., C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman, D. C. Palmer, C. C. Chan, C. A. Klebanoff, W. W. Overwijk, et al. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601.
36. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.
37. Ercolini, A. M., B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J. P. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee. 2005. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201: 1591-1602.
38. Ghiringhelli, F., C. Menard, P. E. Puig, S. Ladoire, S. Roux, F. Martin, E. Solary, A. Le Cesne, L. Zitvogel, and B. Chauffert. 2007. Metronomic cyclophospha-mide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56: 641-648.
39. Wada, S., K. Yoshimura, E. L. Hipkiss, T. J. Harris, H. R. Yen, M. V. Goldberg, J. F. Grosso, D. Getnet, A. M. Demarzo, G. J. Netto, et al. 2009. Cyclophos-phamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res. 69: 4309-4318.
40. Ge, Y., C. Domschke, N. Stoiber, S. Schott, J. Heil, J. Rom, M. Blumenstein, J. Thum, C. Sohn, A. Schneeweiss, et al. 2012. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol. Immunother. 61: 353-362.
41. Walter, S., T. Weinschenk, A. Stenzl, R. Zdrojowy, A. Pluzanska, C. Szczylik, M. Staehler, W. Brugger, P. Y. Dietrich, R. Mendrzyk, et al. 2012. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophospha-mide associates with longer patient survival. Nat. Med. 18: 1254-1261.
42. Tongu, M., N. Harashima, H. Monma, T. Inao, T. Yamada, H. Kawauchi, and M. Harada. 2013. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol. Immunother. 62: 383-391.
43. Lando, Z., D. Teitelbaum, and R. Arnon. 1980. Induction of experimental allergic encephalomyelitis in genetically resistant strains of mice. Nature 287: 551-552.
44. Ikezawa, Y., M. Nakazawa, C. Tamura, K. Takahashi, M. Minami, and Z. Ikezawa. 2005. Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J. Dermatol. Sci. 39: 105-112.
45. Brode, S., T. Raine, P. Zaccone, and A. Cooke. 2006. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177: 6603-6612.
46. Su, Y. C., M. S. Rolph, M. A. Cooley, and W. A. Sewell. 2006. Cyclophos-phamide augments inflammation by reducing immunosuppression in a mouse model of allergic airway disease. J. Allergy Clin. Immunol. 117: 635-641.
47. Brode, S., and A. Cooke. 2008. Immune-potentiating effects of the chemother-apeutic drug cyclophosphamide. Crit. Rev. Immunol. 28: 109-126.
48. Kaur, S., W. L. Tan, C. Soo, C. C. Cheung, J. Stewart, and S. Reddy. 2010. An immunohistochemical study on the distribution and frequency of T regulatory cells in pancreatic islets of NOD mice during various stages of spontaneous and cyclophosphamide-accelerated diabetes. Pancreas 39: 1024-1033.
49. Fisson, S., G. Darrasse-Jèze, E. Litvinova, F. Septier, D. Klatzmann, R. Liblau, and B. L. Salomon. 2003. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J. Exp. Med. 198: 737-746.
50. Tang, A. L., J. R. Teijaro, M. N. Njau, S. S. Chandran, A. Azimzadeh, S. G. Nadler, D. M. Rothstein, and D. L. Farber. 2008. CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis. J. Immunol. 181: 1806-1813.
51. Zitvogel, L., L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8: 59-73.
52. Le, D. T., and E. M. Jaffee. 2012. Regulatory T-cell modulation using cyclo-phosphamide in vaccine approaches: A current perspective. Cancer Res. 72: 3439-3444.
53. Zhao, J., Y. Cao, Z. Lei, Z. Yang, B. Zhang, and B. Huang. 2010. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophos-phamide is explained by reduced intracellular ATP levels. Cancer Res. 70: 4850-4858.
54. Hermans, I. F., T. W. Chong, M. J. Palmowski, A. L. Harris, and V. Cerundolo. 2003. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 63: 8408-8413.
55. Taieb, J., N. Chaput, N. Schartz, S. Roux, S. Novault, C. Ménard, F. Ghiringhelli, M. Terme, A. F. Carpentier, G. Darrasse-Jèze, et al. 2006. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 176: 2722-2729.
56. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lympho-depleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
57. Till, B. G., M. C. Jensen, J. Wang, X. Qian, A. K. Gopal, D. G. Maloney, C. G. Lindgren, Y. Lin, J. M. Pagel, L. E. Budde, et al. 2012. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119: 3940-3950.